Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A carcinoma that arises from epithelial cells of the collecting duct of renal tubule
Biomarker and diagnostic research for collecting duct carcinoma has been reported in the published literature.
6 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 6 PHASE2. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06302569](https://clinicaltrials.gov/study/NCT06302569) |
Data assembled from 4 of 12 sources · Last updated Sep 18, 2026, 4:34 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about collecting duct carcinoma
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma |
PHASE2 |
Giuseppe Procopio |
RECRUITING |
[NCT04071223](https://clinicaltrials.gov/study/NCT04071223) | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study | PHASE2 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
[NCT06211114](https://clinicaltrials.gov/study/NCT06211114) | Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma | PHASE2 | Peking University Cancer Hospital & Institute | RECRUITING |
[NCT04413123](https://clinicaltrials.gov/study/NCT04413123) | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | PHASE2 | Bradley A. McGregor, MD | ACTIVE_NOT_RECRUITING |
[NCT03866382](https://clinicaltrials.gov/study/NCT03866382) | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
40 publications have been identified in PubMed for collecting duct carcinoma. Research spans Case Report / Case Series (45%), Epidemiology / Natural History (18%), and Diagnostic / Biomarker (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 18 | 45% |
Disease patterns and progression | 7 | 18% |
Testing and diagnosis research | 5 | 13% |
Laboratory research | 5 | 13% |
Research summaries | 3 | 8% |
Other research | 1 | 3% |
New treatment approaches | 1 | 3% |
Rametta A (2026). [PMID: 41517842](https://pubmed.ncbi.nlm.nih.gov/41517842/). *Expert review of clinical pharmacology*. [Case Report / Case Series]
Goodstein T (2026). [PMID: 41874435](https://pubmed.ncbi.nlm.nih.gov/41874435/). *Curr Opin Oncol*. [Review / Meta-Analysis]
Zhu C (2026). [PMID: 41869663](https://pubmed.ncbi.nlm.nih.gov/41869663/). *Front Oncol*. [Case Report / Case Series]
Yang J (2026). [PMID: 40644580](https://pubmed.ncbi.nlm.nih.gov/40644580/). *Clinical nuclear medicine*. [Case Report / Case Series]
Zeng X (2026). [PMID: 40992973](https://pubmed.ncbi.nlm.nih.gov/40992973/). *Urologic oncology*. [Case Report / Case Series]
Fukuma Y (2026). [PMID: 41457354](https://pubmed.ncbi.nlm.nih.gov/41457354/). *Toxicol Pathol*. [Basic Science / Preclinical]
Liu Y (2026). [PMID: 41151238](https://pubmed.ncbi.nlm.nih.gov/41151238/). *Ann Diagn Pathol*. [Diagnostic / Biomarker]
Wang X (2026). [PMID: 41729475](https://pubmed.ncbi.nlm.nih.gov/41729475/). *J Ultrasound*. [Diagnostic / Biomarker]
Qu Y (2025). [PMID: 40917497](https://pubmed.ncbi.nlm.nih.gov/40917497/). *Research (Washington, D.C.)*. [Basic Science / Preclinical]
Le Mével LP (2025). [PMID: 39999750](https://pubmed.ncbi.nlm.nih.gov/39999750/). *Clinical genitourinary cancer*. [Epidemiology / Natural History]
AI-curated news mentioning collecting duct carcinoma
Updated Jun 21, 2010
The CDC's Advisory Committee on Immunization Practices (ACIP) is meeting to discuss routine vaccine administration recommendations for children and adults. This includes details on age, dosing intervals, and precautions.